POINT Biopharma Global In... (PNT)
POINT Biopharma Global Statistics
Share Statistics
POINT Biopharma Global has 106.57M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 106.57M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 87.47M |
| Failed to Deliver (FTD) Shares | 35.05K |
| FTD / Avg. Volume | 0.91% |
Short Selling Information
The latest short interest is 3M, so 2.82% of the outstanding shares have been sold short.
| Short Interest | 3M |
| Short % of Shares Out | 2.82% |
| Short % of Float | 3.32% |
| Short Ratio (days to cover) | 1.47 |
Valuation Ratios
The PE ratio is 7.02 and the forward PE ratio is null. POINT Biopharma Global's PEG ratio is -0.03.
| PE Ratio | 7.02 |
| Forward PE | n/a |
| PS Ratio | 3.04 |
| Forward PS | n/a |
| PB Ratio | 1.42 |
| P/FCF Ratio | 4.04 |
| PEG Ratio | -0.03 |
Enterprise Valuation
POINT Biopharma Global has an Enterprise Value (EV) of 403.21M.
| EV / Sales | 1.78 |
| EV / EBITDA | 3.17 |
| EV / EBIT | 2.2 |
| EV / FCF | 2.36 |
Financial Position
The company has a current ratio of 6.66, with a Debt / Equity ratio of 0.
| Current Ratio | 6.66 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -89.98 |
Financial Efficiency
Return on Equity is 20.19% and Return on Invested Capital is 19.55%.
| Return on Equity | 20.19% |
| Return on Assets | 17% |
| Return on Invested Capital | 19.55% |
| Revenue Per Employee | $1.76M |
| Profits Per Employee | $761.96K |
| Employee Count | 129 |
| Asset Turnover | 0.39 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 31.29M |
| Effective Tax Rate | 24.15% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0, so POINT Biopharma Global's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 13.21 |
| 200-Day Moving Average | 9.87 |
| Relative Strength Index (RSI) | 35.38 |
| Average Volume (20 Days) | 3.85M |
Income Statement
In the last 12 months, POINT Biopharma Global had revenue of 226.58M and earned 98.29M in profits. Earnings per share was 1.04.
| Revenue | 226.58M |
| Gross Profit | 226.58M |
| Operating Income | 125.52M |
| Net Income | 98.29M |
| EBITDA | 127.32M |
| EBIT | 128.19M |
| Earnings Per Share (EPS) | 1.04 |
Balance Sheet
The company has 286.43M in cash and 0 in debt, giving a net cash position of 286.43M.
| Cash & Cash Equivalents | 286.43M |
| Total Debt | 0 |
| Net Cash | 286.43M |
| Retained Earnings | 39.01M |
| Total Assets | 477.7M |
| Working Capital | 314.58M |
Cash Flow
In the last 12 months, operating cash flow was 183.52M and capital expenditures -12.77M, giving a free cash flow of 170.75M.
| Operating Cash Flow | 183.52M |
| Capital Expenditures | -12.77M |
| Free Cash Flow | 170.75M |
| FCF Per Share | 1.8 |
Margins
Gross margin is 100%, with operating and profit margins of 55.4% and 43.38%.
| Gross Margin | 100% |
| Operating Margin | 55.4% |
| Pretax Margin | 57.19% |
| Profit Margin | 43.38% |
| EBITDA Margin | 56.19% |
| EBIT Margin | 55.4% |
| FCF Margin | 75.36% |
Dividends & Yields
PNT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 14.25% |
| FCF Yield | 24.76% |
Analyst Forecast
Currently there are no analyst rating for PNT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 16.82 |
| Piotroski F-Score | 6 |